Hormone-Independent Prostate Cancer: Management of the Disease Continuum

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

1989 • 417 citations

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

1993 • 400 citations

Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome

1993 • 354 citations

The memorial pain assessment card. A valid instrument for the evaluation of cancer pain

1987 • 331 citations

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.

1992 • 237 citations

Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer

1992 • 206 citations

Prostate and Bone Fibroblasts Induce Human Prostate Cancer Growth in Vivo: Implications for Bidirectional Tumor-Stromal Cell Interaction in Prostate Carcinoma Growth and Metastasis

1992 • 188 citations

The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate Cancer

1992 • 175 citations

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.

1990 • 146 citations

Systemic therapy for genitourinary cancers

1989 • 61 citations

The Combination of Cyproterone Acetate and Low Dose Diethylstilbestrol in the Treatment of Advanced Prostatic Carcinoma

1988 • 45 citations

Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover.

1987 • 29 citations

Longitudinal Myotomy of Ileum for Bladder Replacement in Dogs

1991 • 17 citations